Coloplast is now rated a cautious 'Buy,' as its valuation has become more reasonable after a significant price correction. Coloplast continues to deliver solid organic growth, boasts a wide economic ...

Investing.com -- Coloplast delivered a solid fourth-quarter performance, with in-line organic sales growth (OSG) matching ...

Coloplast A/S engages in the developing, manufacture, and markets medical products. It operates through the following segments: Chronic Care, Voice and Respiratory Care, Interventional Urology, ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Minnesota - Product Liability - - Minnesota 4th Judicial District, Hennepin County - 27-CV-25-19784 - Janette Ireland v. Coloplast A/s, Coloplast Corporation, Coloplast Manufacturing US, LLC - Janette ...

Minnesota - Product Liability - - Minnesota 4th Judicial District, Hennepin County - 27-CV-25-20028 - Rene Henry v. Coloplast Corporation - Rene Henry - Noah Clarke Lauricella - Coloplast Corporation ...

Because of aging populations in developed countries, the incidence of colorectal disease is growing. Independent of age, the incidence of inflammatory bowel disease is also on the rise.

As of 10:31:01 AM GMT+2. Market Open.